Literature DB >> 26670630

Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.

Myrte B Breukink1, Jacqueline K Mohr1, Annette Ossewaarde-van Norel2, Anneke I den Hollander1,3, Jan E E Keunen1, Carel B Hoyng1, Camiel J F Boon4.   

Abstract

PURPOSE: To evaluate the outcome of a prospective protocol for the treatment of chronic central serous chorioretinopathy (CSC).
METHODS: Interventional prospective case series in 59 eyes (59 patients) with active chronic CSC. All patients were first treated with indocyanine green angiography (ICGA)-guided half-dose photodynamic therapy (PDT). In case of persistent serous subretinal fluid (SRF) after a follow-up period of at least 6 weeks, ICGA-guided PDT was repeated. If the SRF persisted after two PDT treatments, additional ICGA-guided high-density subthreshold diode micropulse laser (HSML) therapy was performed. Clinical evaluation included best-corrected visual acuity (BCVA), fundoscopy, OCT, fundus autofluorescence, fluorescein angiography and ICGA.
RESULTS: After a single PDT treatment, complete resolution of SRF was seen in 37 of 59 eyes. Of the 22 eyes with no complete resolution of SRF, 19 eyes received a second PDT treatment, after which seven eyes of the 19 eyes showed a complete resolution of SRF. Ten eyes underwent HSML, of which one eye had complete resolution of SRF within 7 weeks. At final follow-up a complete resolution of SRF was present in 80% of all eyes. The mean BCVA improved from 0.28 logMAR at baseline to 0.16 logMAR at final follow-up. Improvement of BCVA was highest after the first treatment (-0.12 logMAR, p < 0.001).
CONCLUSIONS: The proposed treatment strategy using half-dose PDT and HSML in active chronic CSC resulted in an anatomical success rate of 80%. The first half-dose PDT treatment has the highest likelihood of a favourable treatment response on OCT and BCVA increase.
© 2015 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic central serous chorioretinopathy; half-dose photodynamic therapy; micropulse diode laser therapy; prospective

Mesh:

Substances:

Year:  2015        PMID: 26670630     DOI: 10.1111/aos.12938

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  10 in total

1.  Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.

Authors:  Brian E Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2017-05-08

2.  Subthreshold Micropulse Treatment Laser versus Half-Dose Photo Dynamic Therapy for the Chronic Central Serous Chorioretinopathy with Parafoveal or Subfoveal Leakage STML versus PDT for Treatment of Chronic CSC.

Authors:  Qingshan Chen; Xia Zhao; Qiuju Yin; Zhi Li; Zimei Zhao; Jiafeng Ning
Journal:  J Ophthalmol       Date:  2022-06-30       Impact factor: 1.974

3.  Role of 532 nm transfoveal subthreshold micropulse laser in non-resolving central serous chorioretinopathy with subfoveal leaks.

Authors:  Vikas Ambiya; Ashok Kumar
Journal:  Ther Adv Ophthalmol       Date:  2020-09-17

4.  Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy.

Authors:  Nadeem Ali Dhirani; Yelin Yang; Sohel Somani
Journal:  Clin Ophthalmol       Date:  2017-12-06

Review 5.  A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders.

Authors:  Paula Scholz; Lebriz Altay; Sascha Fauser
Journal:  Adv Ther       Date:  2017-05-24       Impact factor: 3.845

6.  Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser.

Authors:  Maciej Gawęcki; Agnieszka Jaszczuk-Maciejewska; Anna Jurska-Jaśko; Andrzej Grzybowski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-22       Impact factor: 3.117

7.  Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.

Authors:  Thomas J van Rijssen; Elon H C van Dijk; Greet Dijkman; Camiel J F Boon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-07       Impact factor: 3.117

8.  Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.

Authors:  Elon H C van Dijk; Greet Dijkman; Camiel J F Boon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-03       Impact factor: 3.117

Review 9.  Management of chronic central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Anna C S Tan; Sumit Randhir Singh; Niroj Kumar Sahu; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

10.  Photodynamic therapy for bullous retinal detachment: a single-center experience of case series with a 6-month follow-up study.

Authors:  Tingting Gao; Jinfeng Qu; Jing Xiao; Jie Hu; Mingwei Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-04       Impact factor: 3.117

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.